Free tool
FAERS Monitor: Duaklir Pressair
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210595 or its brand name (Duaklir Pressair, Aclidinium Bromide, Formoterol Fumarate). Reports on generic versions are filed under their own applications.
Reports
29
Serious
6
21% of reports
Hospitalization
4
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product dose omission issue12
- device issue4
- dyspnoea4
- device defective2
- parosmia2
- taste disorder2
- adverse event1
- asphyxia1
- atrioventricular block complete1
- cardiac failure congestive1
- chronic obstructive pulmonary disease1
- confusional state1
- coronavirus infection1
- device delivery system issue1
- drug dose omission by device1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 2 |
| 2020 | 7 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 6 |
| 2026 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,130 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| parosmia | 2 | 192.3 | 50.5 | 213 |
| coronavirus infection | 1 | 109.7 | 16.0 | 26 |
| atrioventricular block complete | 1 | 108.4 | 15.8 | 26 |
| asphyxia | 1 | 88.8 | 12.9 | 21 |
| device defective | 2 | 83.7 | 22.0 | 91 |
| taste disorder | 2 | 71.5 | 18.8 | 78 |
| device issueSignal | 4 | 32.3 | 13.0 | 93 |
| product dose omission issueSignal | 12 | 29.6 | 19.2 | 308 |
| device delivery system issue | 1 | 26.5 | 3.9 | 6 |
| chronic obstructive pulmonary disease | 1 | 13.9 | 2.0 | 3 |
| drug dose omission by device | 1 | 9.3 | 1.3 | 1 |
| cardiac failure congestive | 1 | 9.0 | 1.3 | 1 |
| adverse event | 1 | 7.9 | 1.1 | 1 |
| dyspnoeaSignal | 4 | 5.1 | 2.1 | 10 |
| confusional state | 1 | 4.5 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.